Neuropace

Neuropace LT Debt/Equity

The Long-Term Debt to Equity Ratio of Neuropace (NPCE) as of Nov 13, 2026 is 3.09. In the previous year, Long-Term Debt to Equity Ratio was 7.43 — a change of -58.35% (lower).

LT Debt/Equity

3.09

YoY

-58.35%

Last updated:

Long-Term Debt to Equity Ratio of Neuropace is 2025 3.09 . Long-Term Debt to Equity Ratio of Neuropace was 2024 7.43 . It decreases by -58.35% lower compared to the previous year.

The Neuropace LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2020
-0.34 USD
Jan 1, 2021
0.68 USD
Jan 1, 2022
1.52 USD
Jan 1, 2023
2.76 USD
Jan 1, 2024
7.43 USD
Jan 1, 2025
3.09 USD
The Neuropace LT Debt/Equity history
YEARLT Debt/EquityYoY
3.09-58.35%
7.43+169.39%
2.76+81.24%
1.52+124.36%
0.68-297.27%
-0.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuropace Stock analysis

What does Neuropace do? Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuropace stock

Long-Term Debt to Equity Ratio of Neuropace is 3.09 in 2025.

Long-Term Debt to Equity Ratio of Neuropace changed from 7.43 to 3.09, representing a -58.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Neuropace since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Neuropace with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neuropace

All Key Metrics — Neuropace